On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here.
Re: 17.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Document A68/34
My name is James Love, from Knowledge Ecology International. I wanted to discuss the negotiations on new approaches to funding medical R&D.
I will begin with the much delayed discussions about a WHO R&D treaty, which are supposed to resume in 2016.
We have suggestions for some changes in the discussion, to move things forward.
On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here:
On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_1-en.pdf
On Friday, 8 May 2015, the World Health Organization (WHO) unveiled its 19th WHO Model of Essential Medicines (April 2015).
With respect to cancer drugs (Section 8.2, Cytoxic and Adjuvant Medicines), the Executive Summary noted that the Committee added 16 new medicines.
WHO donors in 2014 (US, Gates Foundation, UK, GAVI and Canada): Setting the agenda for global public health?
In preparation for the 68th World Health Assembly, to be convened in Geneva from 18 May 2015 to 26 May 2015, the World Health Organization (WHO) prepared a document (A68/INF./1, 1 May 2015), entitled “Annex to the Financial Report for the year ended 31 December 2014, Voluntary contributions by fund and by contributor). Continue Reading
Letter from KEI to USPTO regarding implementation of Beijing Treaty
On May 5, 2015, KEI sent a letter to the USPTO regarding the implementation of the Beijing Treaty on Audiovisual Performances. The letter focuses on concerns that KEI and others have expressed that a treaty implementation by amendment of 17 U.S. Code ยง 1101, regarding the “Unauthorized fixation and trafficking in sound recordings and music videos,” creates problems, because the statute involves a right that is perpetual and not subject to normal copyright exceptions. Continue Reading
2015: NIH refuses to give information about principals in company seeking exclusive license to HCV patents
Other KEI comments on NIH licenses are found here: /nih-licenses
USTR’s 2015 Special 301 List
Every year USTR issues a list of countries targeted to be subjected to trade pressures over their policies on intellectual property rights. This year’s list was published on April 30, 2015. KEI has a copy of every version of the Special 301 list here: https://www.keionline.org/ustr/special301
USTR describes the list as follows:
The Special 301 Process
Continue ReadingSeminars on Drug Pricing: Part 1, Paul Grootendorst
Today, KEI hosted the first talk in a series of seminars on drug pricing. The seminar, conducted via video conference, focused on the Canadian approach to drug pricing. Each seminar in the series is intended to contribute to the discussion on drug pricing and how we can improve affordability and access to medicines. Paul Grootendorst began with a presentation (the slides are available here), before opening up the discussion to questions from those participating in the video conference.